Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
May, 2026
May 2026
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Dirk Sibbing Shares Phase 3 Study on Dissaggpro for STEMI – Rapid Onset and Fast Offset of Antiplatelet Action!
Dirk Sibbing/LinkedIn
Sep 25, 2025, 12:25

Dirk Sibbing Shares Phase 3 Study on Dissaggpro for STEMI – Rapid Onset and Fast Offset of Antiplatelet Action!

Dirk Sibbing, Professor, Cardiologist and Angiologist at Lauterbacher Mill Private Clinic and LMU Munich, shared on LinkedIn:

”A new drug on the horizon for pre-hospital treatment of STEMI patients

Subcutaneous GPIIb/IIIa – Dissaggpro

Rapid onset and fast offset of antiplatelet action

Phase 3 Study (CeleBrate) of Novel Anti-Platelet Drug for Heart Attack Reports Positive Topline Results as announced by CeleCor Therapeutics

This, for sure, will bring new aspects into the discussions on pretreatment (antiplatelet) for STEMI patients…

Still we are loosing too many patients pre-hospital and before we see them in the cath lab…

Results will be presented as LBCT at AHA 2025 in New Orleans

Arnoud van ‘t Hof, Robert S. Hillman, Jur ten Berg, C. Michael Gibson, M.S., M.D.”

Read the full article here.

Article: Phase 3 Study of Novel Anti-Platelet Drug for Heart Attack Reports Positive Topline Results

Dirk Sibbing Shares Phase 3 Study on Dissaggpro for STEMI - Rapid Onset and Fast Offset of Antiplatelet Action!

Stay updated on all scientific advances in the field with Hemostasis Today.

AHA 2025 Arnoud van 't Hof C. Michael Gibson CeleBrate CeleCor Therapeutics Dirk Sibbing Dissaggpro Health Hematology Hemostasis Hemostasis Today Jur ten Berg LBCT Medicine Robert S. Hillman STEMI thrombosis
NewsFeed